Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisaftoclax - Ascentage Pharma

Next Previous
Drug Profile

Lisaftoclax - Ascentage Pharma

Alternative Names: APG-2575

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics; Benzamides; Dioxanes; Piperazines; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Waldenstrom's macroglobulinaemia; Acute myeloid leukaemia; Multiple myeloma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia
  • Phase I/II Amyloidosis; Breast cancer; Multiple myeloma; Solid tumours; Systemic lupus erythematosus; Waldenstrom's macroglobulinaemia
  • Phase I Chronic myeloid leukaemia; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Preclinical Gastrointestinal stromal tumours
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 08 Sep 2025 First Affiliated Hospital of Zhejiang University plans a phase I/II trial for Diffuse large B-cell lymphoma and Non-Hodgkin lymphoma (Second-line therapy or greater) in China (PO) (NCT07159906)
  • 20 Aug 2025 Launched for Chronic lymphocytic leukaemia (Second-line therapy or greater) in China (PO)
  • 17 Aug 2025 European Medicines Agency approves IND application for lisaftoclax in Myelodysplastic syndromes (Combination therapy, First-line therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top